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With an increase in the elderly population and an increase in the prevalence of age-related cardiovascular disease, 
anesthesiologists are increasingly being faced with elderly patients with known or suspected ischemic heart 
disease in the perioperative period.  Although early reperfusion remains the best strategy to reduce ischemic 
injury, reperfusion may damage the myocardium. Adjuvant therapy to revascularization is therefore necessary.  To 
develop better strategies to prevent ischemia-reperfusion injury in older patients, we need to understand the aged 
myocardium, which has undergone structural and functional changes relative to the normal myocardium, resulting 
in reduced functional capacity and vulnerability to ischemia-reperfusion injury.  In addition, innate or acquired 
cardioprotection deteriorates with aging.  These changes in the aged myocardium might explain why there is poor 
translation of basic research findings from young animals to older patients. In this review, I discuss changes in 
intracellular signaling associated with myocardial ageing that have an effect on ischemia-reperfusion injury, and I 
discuss the efficacy of cardioprotection afforded by ischemic and pharmacologic pre- and post-conditioning in the 
aged myocardium.  Finally, I outline strategies to restore protection in the aged myocardium. (Korean J Anesthesiol 
2010; 58: 223-230)
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Introduction
    The incidence and prevalence of cardiovascular diseases, 
including ischemic heart disease, are increasing in Korea, most 
likely due to the ageing of the population and adoption of a 
Westernized diet. Cardiovascular disease is the leading cause 
of mortality in the elderly. Two-thirds of myocardial infarctions 
occur in individuals older than 65 years-of-age, and 80% of 
deaths caused by myocardial infarction are in elderly patients. 
These data indicate that ischemic heart disease is prevalent in 
the elderly, and that the mortality due to ischemic heart disease 
increases with ageing. According to the National Statistical 
Office, individuals aged 65 years or older comprised 9.9% of 
the Korean population in 2007, and this figure is expected 
to exceed 14% in 2013, thus Korea is expected to become an 
‘aged society’ in the near future. With the rapid increase in the 
elderly population, the incidence of ischemic heart disease in 
these elderly individuals is also expected to increase rapidly. 224 www.ekja.org
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Aggressive therapeutic strategies may be required to treat 
ischemic heart disease in the elderly in order to improve their 
qualities of life. 
    Although reperfusion remains the best strategy for the 
treatment of ischemic heart disease, reperfusion itself injures 
the myocardium. A study that targeted patients with acute 
myocardial infarction showed that mortality is higher and left 
ventricular dysfunction is greater in patients aged 75 years or 
older despite successful revascularization with thrombolysis 
[1]. This study proved that the aged myocardium is sensitive 
to reperfusion injury. Off-pump coronary artery bypass graft 
surgery has increased the prevalence of cardiac surgery 
performed in the elderly. Although off- pump coronary artery 
bypass graft surgery has several advantages such as less 
neurologic complications and less inflammatory reactions, 
ischemia-reperfusion injury is not avoidable because of the 
elevation of the heart during surgery and transient occlusion 
for coronary anastomosis. Thus, it is very important to develop 
strategies to reduce ischemia-reperfusion injuries in the aged 
myocardium during the perioperative period.
    A multitude of studies have investigated strategies to 
protect the heart against ischemia-reperfusion injury, 
either by ischemic pre- and post-conditioning or by mimics 
of pharmacologic stimuli. However, the clinical data are 
inconsistent. The poor translation of basic research results to 
clinical application may be due to the characteristics of the 
target population; although most experimental studies have 
been performed in healthy young animals, the patients in the 
operating room are diseased and old. We therefore need to 
understand the aged myocardium in order to develop strategies 
to reduce myocardial ischemia-reperfusion injuries in these 
patients. 
    In this review, I discuss (1) functional and structural changes 
in the aged myocardium, especially mitochondrial changes, (2) 
the increased susceptibility to ischemia-reperfusion injury that 
is characteristic of the aged myocardium, including the changes 
in intracellular signaling important to ischemia-reperfusion 
injury, (3) loss of cardioprotection with ageing, and finally (4) 
strategies to restore protection in the aged myocardium.
Functional and structural changes in the 
aged myocardium
    Ageing affects cardiomyocytes at different levels. At 
the level of DNA, mutations and telomere shortening are 
observed in the aged myocardium. Telomere shortening 
might be associated with limited regenerative capacity [2] 
and increased mortality [3]. Based on changes in nuclear and 
mitochondrial gene expression profiles, protein expression in 
the aged myocardium is altered and is associated with a shift 
from fatty acid to carbohydrate metabolism and changes in 
intracellular matrix and signal transduction components [4]. 
The handling of cellular waste by autophagy is also altered. 
Aged cardiomyocytes have decreased tolerance to stress such as 
ischemia-reperfusion and increased susceptibility to apoptosis 
and necrosis. Increased apoptosis and necrosis reduce the 
number of cardiomyocytes and result in the development of 
hypertrophy in the remaining cardiomyocytes. All of these 
changes decrease contractile function, resulting in decreased 
left ventricular systolic and diastolic function and decreased 
peak cardiac output [5].
    Mitochondria are the powerhouses of the cell. Energy 
supplied by mitochondrial oxidative phosphorylation provides 
more than 70% of the ATP that the myocardium requires [6]. 
Mitochondria also control ion homeostasis, generate reactive 
oxygen species (ROS), and are involved in apoptotic/anti-
apoptotic signaling. Aged cardiomyocytes are sensitive to 
oxidative stress, which injures mitochondria and makes them 
larger. These giant mitochondria are not removed by autophagy, 
and they accumulate in the cardiomyocytes. These injured 
mitochondria contain damaged, mutated DNA, resulting 
in the production of mutant proteins, which accelerate ROS 
generation in aged cardiomyocytes. In addition to excessive 
generation of ROS, the antioxidant capacity of cells decreases 
with aging due to increases in levels of manganese-containing 
superoxide dismutase and decreases in either catalase or 
glutathione. Mitochondria also play an important role in 
endogenous cardioprotection. The opening of the mitochondria 
permeability transition pore (MPTP) is critical for the initiation 
of cell death [7]. In aged mitochondria, MPTP opening has been 
observed to be more sensitive than that in young mitochondria [8].
    The expression and/or activity of protein kinases, which play 
a critical role in cardioprotection, are also altered in the aged 
myocardium (Table 1). The expression level or phosphorylation 
status of reperfusion injury salvage kinase (RISK) elements, 
including Akt (protein kinase B), ERK1/2 (extracellular signal-
regulated kinase 1/2), and GSK 3β (glycogen synthase kinase 
3β), are altered in the aged myocardium. Phosphatases 
such as protein phosphatase 2A (PP2A) or protein tyrosine 
phosphatase 1B (PTP1B, which reduce phosphorylation of 
proteins and suppress their activation, are increased. Levels 
of Cx43 (connexin 43), STAT3 (signal transducer and activator 
of transcription 3), and Sirt 1 (sirtuin), which play a role in 
cardioprotection, are also decreased.
    Aged cardiomyocytes are susceptible to calcium overloading 
[8,9] because of a reduction in the density and activity of 
calcium regulating proteins such as the Na
+/Ca
2+ exchanger, 
Ca
2+ ATPase, and ryanodine receptor [10-13]. In addition, 
modification of the amount and composition of cardiolipin in 
mitochondria [14] contributes to the breakdown of calcium 225 www.ekja.org
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homeostasis, which is susceptible to the opening of MPTP [15]. 
Ischemia-reperfusion injury in the aged 
myocardium
    Advanced age is an independent risk factor for poor cardiac 
outcome. With ageing, comorbidities such as hypertension, 
atherosclerosis, congestive heart failure, or diabetes may affect 
the sensitivity of the aged myocardium to ischemia-reperfusion 
injury. However, several studies have shown that increased 
mortality in the elderly is independent of the presence of 
hypertension, diabetes, previous myocardial infarction, number 
of diseased coronary arteries, and the location of infarction 
[15,27]. These results indicate that the aged myocardium is 
vulnerable to ischemia-reperfusion injury.
    The aged myocardium has decreased tolerance to ischemia-
reperfusion injury, though the ischemic threshold is not 
affected by age (Fig. 1). Decreased tolerance to ischemia-
reperfusion injury has been demonstrated in middle-aged mice 
(12 months); this decreased tolerance became more prominent 
with ageing (18 months and 24-28 months) [29]. However, the 
results from a study of the human atrium were inconsistent. 
Although creatine kinase release after 90 min of ischemia 
followed by 120 min of reperfusion was not affected by age 
[30], the recovery of contractile force after 30 min of hypoxia 
followed by 30 min of reoxygenation was reduced in the atrium 
of patients aged 60 years or older compared to that of adults 
younger than 60 years [31]. 
    The increased susceptibility to ischemia-reperfusion injury 
seen in the aged myocardium might be associated with 
enhanced oxidative stress. Oxidative damage was found to 
be aggravated in the aged myocardium of 20-month-old rats 
[30] and reperfusion with superoxide dismutase and catalase 
improved contractile function. Furthermore, treatment of the 
aged myocardium of 24-month-old rats with acetylcarnitine 
improved the recovery of contractile function and reduced 
lactated dehydrogenase levels [32].
Loss of protection in the aged myocardium
Ischemic preconditioning (IPC)
    Since the first demonstration of ischemic preconditioning 
in 1986 by Murray et al., IPC has been considered to be one of 
the strongest forms of endogenous cardioprotection. IPC has 
two different phases; an early phase that develops within a few 
minutes and lasts up 2-4 hours and a late phase that develops 
6-12 hours and lasts up to 4 days. Complex intracellular 
signaling pathways mediate IPC, and ROS generated in the 
mitochondria act as triggers or mediators. Although several 
effector candidates have been evaluated, the evidence that 
MPTPs or mitochondrial KATP channels are the effectors is most 
convincing (Fig. 2). Although simplification of the cascades 
into a trigger, mediator, and effector can help to clarify the 
mechanism of IPC, it should be kept in mind that there is cross-
talk between the underlying signaling components and that the 
underlying mechanism is more complex. 
    The effect of ageing on the ability of preconditioning to protect 
Table 1. Age-associated Alterations in the Expression/Activity of 
Proteins Involved in Cardioprotection
Protein
Species/Age 
(months)
Expression/Activity Reference
MnSOD 
Catalase
PKCε
ERK1/2 
Akt 
GSK 3β
MKP-1  
PTP1B
PP2A
Cx43 
STAT3 
Sirt 1
iNOS 
Rat /24 mo
Rat/31-34 mo 
Rat/24 mo
Mouse/>13 mo 
Rat/24 mo 
Rat /18 mo
Rat/ 23 mo
Mouse/26-28 mo
Rat/ 23 mo
Mouse/20-24 mo
Mouse/26-28 mo
Rat/ 21-22 mo
Mouse/>13 mo
Mouse/>13 mo
Rat/24 mo
Mouse/16 mo
Mouse 28-31 mo 
Decreased
No change in protein level
Decreased SOD activity
Decreased
No change
Decreased
Decreased
Increased phosphorylation 
Decreased total form
Decreased
Increased
Increased
Increased
Decreased
Decreased
Decreased
Increased
Increased
[16]
[17]
[16]
[18]
[19]
[20]
[21]
[22]
[21]
[23]
[22]
[23]
[18]
[18]
[16]
[24]
[25]
MnSOD: manganese superoxide dismutase, PKCε: protein kinase Cε, 
ERK1/2: extracellular signal-regulated kinase 1/2, Akt: protein kinase 
B, GSK3β: glycogen synthase kinase 3β, MKP-1: mitogen-activated 
kinase phosphatase 1, PTP1B: protein tyrosine phosphatase 1B, 
PP2A: protein phosphatase 2A, Cx43: connexin 43, STAT3: signal 
transducer and activator of transcription 3, Sirt1: sirtuin, iNOS: 
inducible nitric oxide synthase,  mo: month.  Table is modified from 
ref [26].
Fig. 1. Effect of reducing coronary perfusion pressure on myocardial 
lactate production in adult and old hearts. This figure is taken from [28].226 www.ekja.org
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hearts from ischemia-reperfusion injury has been studied 
intensively (Table 2). The majority of studies demonstrated 
loss of cardioprotection by IPC with ageing. However, IPC was 
preserved in 2- 4-year-old rabbits [38] and 5.7- to 8-year-old 
sheep [39]. Based on the maximal life span of these species 
(Table 3), however, it is unlikely that these animals are suitable 
models for investigating ageing in humans. 
    When preconditioning stimuli were increased, cardio-
protection was achieved in middle-aged rats. However, cardio-
protection induced by IPC was lost in the aged rats, irrespective 
of the strength of the stimuli (Fig. 3). Indirect data using agonists 
for receptors or channel openers involved in cardioprotection 
showed that IPC signaling cascades are impaired in the aged 
myocardium [37].
    IPC has been shown to occur naturally in the form of pro-
dromal angina prior to acute myocardial infarction, reducing 
the infarct size in patients [41,42]. In clinical studies, the 
measurement of infarct size is not available as an end-point, 
and surrogate end-points are used. For examples, ST changes 
on EKG, biologic markers such as creatine kinase (CK), CK-
MB, and troponin-T, and clinical outcomes such as recovery 
of cardiac functions, length of hospital stay, mortality, and 
Table 2. Effects of Age on Cardioprotection by Ischemic Preconditioning
Species Model Age Endpoint Cardioprotection in the aged heart Reference
Rat
Rat
Rat
Rat
Rat
Mouse
Rabbit
Sheep
Isolated heart
Isolated heart
Isolated heart
Isolated heart
Isolated heart
In vivo
In vivo
In vivo
12 wk/50 wk
2 mo/6 mo/20 mo
6 mo/20 mo
6 mo/24 mo
3 mo/12 mo/18-20 mo
<3 mo/>13 mo
2 yr/4 yr
0.5-1 yr/5.7-8 yr
Hemodynamic, CK
Hemodynamics
Hemodynamics
Hemodynamics
Infarct size
Infarct size
Necrosis
Infarct size
No 
No
No in sedentary
Yes in trained
No in AD Lib,
Yes in CR
No
No
Yes
Yes
[33]
[34]
[35]
[36]
[37]
[18]
[38]
[39]
mo: month, wk: week, yr: year, AD Lib: Ad libitum, CR: caloric restriction.
Table 3. Maximal Life Span [40]
Species Maximal life span
Mouse
Rat
Rabbit
Sheep
Dog
Pig
Human
42 mo
48 mo
13 yr
20 yr
22 yr
27 yr
122 yr
Fig. 2. Cascades of ischemic precon-
ditioning.
Fig. 3. Effect of one 5-min preconditioning cycle (1PC) and three 
5-min preconditioning cycles (3PC) on infarct size in young-adult, 
middle-aged, and aged rat hearts. C: control. This figure was taken 
from [37].227 www.ekja.org
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morbidity are frequently used. Clinical studies of IPC during 
revascularization and prodromal angina within a 48 h prior 
infarction have consistently demonstrated that IPC is not 
cardioprotective in elderly patients in terms of recovery of 
cardiac function, biologic markers, or clinical outcomes [43-45]. 
However, in vitro studies have showed less consistent results. 
After IPC in elderly patients, biological markers such as CK 
were reduced, but contractile function did not improve. Apart 
from age, comorbidities and medications such as angiotensin-
converting enzymes [46,47], COX-2 inhibitors, or sulfonylureas 
[48] complicate analysis of the IPC effect in the elderly. 
Pharmacologic preconditioning 
    Anesthetic preconditioning (APC) by isoflurane was found to 
be effective in middle-aged (10-12 months), but not in aged rat 
hearts (20-24 months) [49,50]. Similarly, in isolated guinea-pig 
hearts, APC by sevoflurane was attenuated with ageing. Helium 
preconditioning-induced cardioprotection was not preserved 
in aged rat hearts [51], and enkephalin preconditioning did not 
protect aged mouse hearts (24-26 months) [52]. Interestingly, 
chronic morphine treatment was shown to be cardioprotective 
via protein kinase A in the aged heart in contrast to loss of acute 
morphine treatment in the aged heart [53]. 
    Several components of the aged myocardium, included 
cardioprotection by APC, may be defective. The increase in 
ROS due to APC is impaired in the aged myocardium, even 
though the baseline ROS level is high in the aged myocardium 
[49]. Coupling between the opioid receptor and p38 MAPK 
(mitogen-activated protein kinase) was shown to be lost in the 
aged mouse heart, and phosphorylation of the downstream 
protein HSP27 (Heat shock protein 27) was reduced [52,53]. 
Ischemic and pharmacologic postconditioning
    Interventions performed at reperfusion to protect the myo-
cardium, such as post-conditioning, may be more clinically 
relevant because it is difficult to anticipate when an ischemic 
event will occur. IPC is not cardioprotective in aged mice 
[23]. However, the cardioprotective effect of IPC depends 
on the stimuli strength in the middle-aged myocardium 
[54]. The loss of the IPC effect in the aged myocardium was 
associated with reduced expression and phosphorylation of 
STAT3 [54,55]. Furthermore, levels of the phosphatase MKP-
1 were increased in the aged myocardium, and inhibition 
of MKP-1 resulted in the restoration of cardioprotection by 
ischemic postconditioning [23]. ERK, a target protein of MKP-
1, was not activated by ischemic postconditioning in the aged 
myocardium, but was restored in aged hearts treated by a MKP-
1 inhibitor [38]. Therefore, in the aged heart, impaired activation 
of ERK 1/2 might affect downstream components such as 
STAT3. I found that isoflurane-induced postconditioning 
was not cardioprotective in old rats (20-24 months) (data 
not published). The reperfusion salvage kinase pathway, 
including Akt, its downstream effector GSK3β, and ERK1/2 
was not activated by anesthetic postconditioning, which may 
be associated with the loss of cardioprotection in the aged rat 
heart. Therefore, the aged myocardium is not protected by pre- 
or post-conditioning, which is associated with impaired signal 
transduction pathways.
Restoration of protection in the aged my-
ocardium
Diet 
    Caloric restriction attenuates cellular ageing and promotes 
longevity [4,56]. Furthermore, caloric restriction renders 
cardiomyocytes resistant to ischemic injury. In food-restricted 
old rats, the cardioprotective effect of ischemic precondition 
was preserved [36]. Recovery of the developed pressure after 
ischemia-reperfusion and the occurrence of arrhythmia were 
evaluated in 6- and 24-month-old rats that had been on a caloric 
restriction diet since weaning [36,57]. The recovery of developed 
pressure was partially improved and arrhythmia was reduced 
in the food-restricted old rats. In a study of short-term caloric 
restriction, 24-month-old rats were fed 90% of their caloric 
intake ad libitum for 2 weeks followed by 65% of their caloric 
intake ad libitum for 2 weeks. The left ventricular pressure 
was then evaluated in isolated perfused hearts. These authors 
found that short-term caloric restriction improved tolerance 
to ischemia, but did not restore IPC-induced cardioprotection 
[57]. Increased tolerance to ischemia by short-term caloric 
restriction was related to increased phosphorylation of AMP-
activated kinase [58]. Increased levels of adiponectin induced 
by caloric restriction may contribute to the restoration of the 
IPC effect in aged hearts [58,59]. 
Exercise
    Exercise contributes to the preservation of endogenous 
cardioprotection in the aged heart. Elderly rats (24-month-old) 
were trained using a swimming protocol of 40 min/day, 5 days/
week for 6 weeks. Developed pressure in the left ventricle was 
partially improved by IPC in these trained rats. However, the 
combination of caloric restriction and exercise restored IPC-
based cardioprotection more completely [60]. The mechanisms 
of exercise-induced cardioprotection or restoration of 
endogenous cardioprotection are not clear. However, a 
reduction in mitochondrial ROS formation, increased coronary 228 www.ekja.org
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circulation, increased levels of antioxidants such as manganese 
superoxide dismutase and catalase, altered expression of 
mitochondrial and sarcoplasmic KATP channels, and altered 
gene/protein expression/activation of factors such as HSP and 
IGF-1 may contribute to exercise-induced cardioprotection [62].
    The beneficial effects of exercise on IPC-induced cardio-
protection have been demonstrated in elderly patients. High 
levels of physical activity preserve the cardioprotective effect of 
prodromal angina in elderly patients [62].
Conclusions
    The prevalence of elderly patients with ischemic heart disease 
is expected to increase as life expectancy and the prevalence 
of ischemic heart disease increase. We therefore need to 
understand the characteristics of the aged myocardium and 
develop strategies to limit ischemia-reperfusion injury in the 
aged myocardium. Even though the mechanisms of increased 
susceptibility to ischemia-reperfusion and loss of protection in 
the aged heart are not fully elucidated, the aged myocardium is 
known to undergo structural and functional changes associated 
with impaired signal transduction. These changes may be 
associated with increased vulnerability to ischemia-reperfusion 
injury and loss of cardioprotection characteristic of the aged 
myocardium. 
    Most experimental studies have evaluated APC in healthy 
juvenile hearts. Unfortunately, this is far from the clinical 
reality. Most cardiac events in humans occur later in life, 
and most patients have comorbidities such as diabetes or 
hypercholesterolemia. Importantly, aged and diseased 
hearts behave differently from younger and healthier hearts. 
Future studies should focus on targeting populations with 
an aged or diseased myocardium. Furthermore, a more 
detailed understanding of the molecular mechanisms altered 
in the aged myocardium is required to identify candidates 
for pharmacologic manipulation. If cardioprotection is not 
triggered by ageing or certain drugs, cardioprotection can be 
provoked by activation of cell surface receptors. However, if 
activation of receptors or intracellular transduction signaling 
pathways is impaired, pharmacological agents acting proximal 
to or at the end-effector might bypass the age-related defects 
and provide cardioprotection. For example, inhibitors of 
MPTP might be cardioprotective in the aged myocardium 
by preventing the opening of the MPTP. However, it is not 
yet known whether functioning of the MPTP is altered in the 
aged myocardium, and the function of the MPTP has not been 
thoroughly elucidated.
    Although exercise and caloric restriction might potentially 
restore endogenous cardioprotection, these are primary 
prevention strategies rather than strategies adjuvant to 
revascularization. Stem cell therapy may replace the damaged 
myocardium or restore endogenous cardioprotection in 
the aged myocardium [38,63]. However, the differentiation, 
replication, and long-term stability of stem cells need to be 
studied further. Research on the mechanisms of endogenous 
cardioprotection and their alteration with ageing is required 
to develop effective strategies to reduce ischemia-reperfusion 
injury in the elderly. 
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